China in the Fast Lane: How to play and win in the world's hottest emerging market
Watch this webcast where Marc Yates and Helen Ansell explored China's evolving healthcare envrinoment. The webcast highlights the key changes affecting pharma and demonstrates how to build the market understanding required to laucnch a brand effectiviely in this exciting region.
Research Partnership publishes new patient Living with Rheumatoid Arthritis (EU, Japan & Canada) 2019 reports
Living with Rheumatoid Arthritis is a report based on 416 patients diagnosed with RA in the 5 EU markets (France, Germany, Italy, Spain, UK), 51 patients in Japan and 107 patients in Canada. The study consists of 30-minute quantitative online and qualitative telephone interviews with patients. The qualitative interviews are enhanced with insights generated from pre-interview patient exercises – such as patient diary entries - to capture in-the-moment feelings about living with rheumatoid arthritis. These reports can be purchased as a package or individually.
Data Analytics & Insight Conference 2019
Last month Analytics Director Misti Paul attended the Data Analytics & Insight Conference in London.
The analytics industry is experiencing unparalleled growth, fueled by big data, artificial intelligence, machine learning and social media analysis. According to statistics provided by the Market Research Society, the analytics industry has experienced 350% growth since 2012. Key drivers of this growth have been disruptive innovation, exponential growth of data, data warehousing, architecture and analytics. However, the shortage of skilled analysts and data scientists remains a barrier in this industry. Many organisations are still learning and grappling with ways to integrate analytics in their business.
How we helped our client to understand the opportunities across Asia and other emerging markets using interactive outputs
Our client needed to understand why the use of statins in type 2 diabetes patients in South Korea, China, Thailand and other developing countries is low / sub-optimal.
Our client needed to understand why the use of statins in type 2 diabetes patients in South Korea, China, Thailand and other developing countries is low and sub optimimal. Research was required to understand the diabetic patient journey in order to assess the opportunities to expand HCP knowledge on the importance of lipid lowering for type 2 diabetes patients. The client also wanted to explore the drivers and barriers which would influence uptake.
Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).